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We thank Dr. De Rosa and colleagues for the interest in our work
(1,2). We agree that the AIDA STEMI (Abciximab i.v. Versus i.c.
in ST-elevation Myocardial Infarction) trial might have been un-
derpowered to detect small differences in clinical event rates be-
tween the treatment arms (if there are any). The absolute difference
in the incidence of the primary endpoint between groups was only
0.6%. Thus, if one were to plan a new trial with a similar design
considering this numerical difference as the true population value,
the required total sample size would exceed 70,000 patients to reach
statistical signiﬁcance. It remains speculative whether particular
(supposedly high-risk) patients might nevertheless beneﬁt from
intracoronary bolus delivery. However, there was no beneﬁt of
intracoronary bolus administration in any of the subgroups studied
with the exception of female patients (which might be a chance
ﬁnding given the lack of a plausible biological explanation). In light
of the meta-regression analysis presented by Dr. De Rosa and
colleagues, which suggested that there is a beneﬁt of intracoronary
abciximab in patients with decreased left ventricular ejection frac-
tion (LVEF), we performed an exploratory subgroup analysis in
AIDA STEMI trial patients with an LVEF <50% and 50% with
respect to the composite endpoint at 1 year. There was no evidence
of a beneﬁcial effect of intracoronary abciximab in patients with
reduced LVEF (LVEF <50%: event rates 14.6% intracoronary vs.
16.0% intravenous; odds ratio: 0.90 [95% conﬁdence interval: 0.58
to 1.39]; LVEF 50%: event rates 5.7% intracoronary vs. 4.5%
intravenous; odds ratio: 1.27 [95% conﬁdence interval: 0.74 to
2.18]; p value for interaction ¼ 0.34). These clinical ﬁndings are
supported by the magnetic resonance substudy of the AIDA
STEMI trial, which found no signiﬁcant differences for established
surrogate markers such as infarct size and microvascular obstruction
between intracoronary and intravenous bolus administration (3).
Further, in the recently published INFUSE-AMI trial including
only high-risk ST-segment elevation myocardial infarction patients
with proximal or mid-left anterior descending artery occlusion, the
magnitude of the absolute infarct size reduction with intracoronary
bolus abciximab (without subsequent low-dose infusion) versus
no abciximab was only modest and was not accompanied by other
markers of reperfusion success (4).
In the era of a high percentage of pre-loading with other potent
antiplatelet agents such as prasugrel and ticagrelor, the magnitude
of the short-lived local effect of direct intracoronary abciximab
bolus delivery might simply not be enough to produce clinically
meaningful effects.*Steffen Desch, MD
Ingo Eitel, MD
Oana Brosteanu, PhD
Gerhard Schuler, MD
Holger Thiele, MD
*Department of Internal Medicine/Cardiology
University of Leipzig Heart Center
Strümpellstrasse 3904289 Leipzig
Germany
E-mail: stdesch@web.de
http://dx.doi.org/10.1016/j.jacc.2013.11.036
Please note: The AIDA STEMI trial was sponsored by the University of Leipzig
Heart Centre and the University of Leipzig Clinical Trial Centre, which is supported
by the Federal Ministry of Education and Research (Bundesministerium fur Bildung
und Forschung, BMBF). An unrestricted research grant was obtained from Eli Lilly,
Germany.REFERENCES
1. Desch S, Wohrle J, Hambrecht R, et al. Intracoronary versus intravenous
abciximab bolus in patients with ST-segment elevation myocardial
infarction: 1-year results of the randomized AIDA STEMI trial. J Am
Coll Cardiol 2013;62:1214–5.
2. Thiele H, Wohrle J, Hambrecht R, et al. Intracoronary versus intrave-
nous bolus abciximab during primary percutaneous coronary intervention
in patients with acute ST-elevation myocardial infarction: a randomised
trial. Lancet 2012;379:923–31.
3. Eitel I, Wohrle J, Suenkel H, et al. Intracoronary compared with
intravenous bolus abciximab application during primary percutaneous
coronary intervention in ST-segment elevation myocardial infarction:
cardiac magnetic resonance substudy of the AIDA STEMI trial. J Am
Coll Cardiol 2013;61:1447–54.
4. StoneGW,MaeharaA,WitzenbichlerB, et al. Intracoronary abciximaband
aspiration thrombectomy in patients with large anterior myocardial infarc-
tion: the INFUSE-AMI randomized trial. JAMA 2012;307:1817–26.Amino Terminal
Fragment of
Pro–B-Type Natriuretic
Peptide for Complex
Congenital Heart
Diseases
One for All, All for One?
We read with interest the paper of Eindhoven et al. (1) under-
scoring the clinical usefulness of N-terminal pro–B-type natriuretic
peptide (NT-proBNP) in adult patients with different congenital
heart diseases (CHDs), even corrected or palliated. Plasma levels of
NT-proBNP differing by diagnosis were correlated with most
relevant echocardiographic morphological and functional indexes,
as well as in a subset of patients undergoing cardiopulmonary stress
testing, with exercise capacity. This work extends actual knowledge
of the utility of both BNP and NT-proBNP as diagnostic tools in
adult patients with CHD (2–8), conﬁrming known age and sex
inﬂuence while specifying a differential role of left and right ven-
tricular involvement with regard to natriuretic peptide (NP) pro-
duction and secretion in each CHD analyzed. Moreover, the work
conﬁrms that the NP level is associated with functional capacity,
even in asymptomatic CHD patients (2–5).
The authors must be congratulated for their successful attempt to
analyze the effect of surgical correction/palliation of NT-proBNP
levels in adults with different CHDs. They add the notion that
